

Table 2.9. Cohort studies of KSHV and multiple myeloma

Reference, location, name of study	Cohort description	Detection method	No. of cases/deaths	Relative risk* (95% CI)	Adjustment for potential confounders	Comments
Tedeschi <i>et al</i> (2001) Finland	Population health survey between 1968 and 1972 of a cohort of 20243 Finnish men and 18,814 women using a mobile health clinic of the Social Insurance Institution. Subjects provided a serum sample and baseline questionnaire over 23 yr F.U. Nationwide linkage of the serum bank to the Finnish Cancer Registry identified 47 cases of MM at the end of 1991. These were matched 5:1 (n=224) with subjects free of cancer at baseline and remained alive up to the time of the case.	IFA Lytic				
		No	34 (Cases)	2.0 (0.9-4.3)	Subjects with MM were age, sex, and area matched	
		Yes	13			
		Latent (LANA)				
		No	45	10.0 (0.9-110.3)		
		Yes	2			
		WB ORF 65 or ORFK8.1A or ORF 73				
		No	44	0.89 (0.25-3.25)		
		Yes	3			
		WB ORF65				
		No	46	0.37 (0.05-2.99)		
		Yes	1			
WB ORF73						
No	47	-				
Yes	0					
WB ORFK8.1A						
No	44	3.18 (0.7-14.47)				
Yes	3					

Table 2.9. Cohort studies of KSHV and multiple myeloma

Reference, location, name of study	Cohort description	Detection method	No. of cases/deaths	Relative risk* (95% CI)	Adjustment for potential confounders	Comments
Tedeschi <i>et al</i> (2005) Scandinavia, Nordic cohort	1 133 000 individuals who had donated serum and/or plasma, pooled from 5 cohorts (Finnish Maternity Cohort of 700 000 pregnant women since 1983; Helsinki Heart Study of dislipidaemic volunteer men from government agencies and five industrial companies; Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study during 1980-1982; Janus project; Northern Sweden Health and Disease Study) started in 1973 collecting blood samples for scientific use, included are 315000 individuals from whole of Norway and blood donors from Oslo and surrounding area. Northern Sweden Health and Disease study of 70000 individuals of 40, 50 and 60 years in Vasterbotten county recruited between 1985 – 1995. 329 cases of multiple myeloma identified through Nordic cancer registries (diagnosis > 1 month after serum sampling); 5 controls per case matched on length of follow-up, biobank, sex, age at serum sampling, time of blood withdrawal	Mouse monoclonal antibody enhanced immunofluorescence assay (IFA) for the detection of antibodies directed against latent or lytic HHV8 antigens.	IFA lytic No 290 Yes 39 IFA latent No 327 Yes 2	1.0 1.08 (0.5–1.1) 1.0 0.6 (0.1–2.7)	Matching variables, incl. age – closely matched, date of serum sampling sex, length of follow-up. In Norway also matched for county of residence.	Similar results for different lag periods. 376 serum samples also tested for HHV8 DNA (quantitative real-time PCR); all samples tested negative Lab blinded to case control status of subjects